Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

4.190 +0.230 (+5.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
What to Expect from Altimmune's Earnings ↗
 
Via Benzinga
News headline image
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts ↗
Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Via ACCESS Newswire
News headline image
Top movers in Thursday's session ↗
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Gapping stocks in Thursday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
News headline image
Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate ↗
Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes. 
Via Benzinga
News headline image
Dow Surges 200 Points; US GDP Contracts 0.5% ↗
 
Via Benzinga
Topics Stocks
News headline image
Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position ↗
Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo. 
Via Stocktwits
News headline image
Thursday's pre-market session: top gainers and losers ↗
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win ↗
Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape. 
Via Stocktwits
News headline image
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? ↗
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement. 
Via Benzinga
News headline image
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased ↗
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH). 
Via Stocktwits
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.